OR WAIT null SECS
May 13, 2020
Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma entered into long-term development and manufacturing services agreements for the clinical and commercial supply of multiple bluebird bio therapies.
May 05, 2020
Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.
The companies have entered into a manufacturing agreement to supply leronlimab, an investigational new drug currently being used in clinical trial protocols for COVID-19.
May 02, 2020
Bioprocessing advances improve product yield, cut costs, and streamline integration between upstream and downstream processes.
May 01, 2020
The new cell-line producing platform enables fully scalable production of high-performance adeno-associated virus vectors.
The goal of the collaboration is to manufacture up to one billion does per year of mRNA-1273, Moderna’s vaccine against the novel coronavirus.
April 30, 2020
Solentim and ATUM will bundle together the Leap-In Transposase platform with the VIPS single cell cloning instrument for cell line development.
April 16, 2020
Dutch company HALIX has announced it is joining a consortium of partners that are all under the guidance of the University of Oxford to provide good manufacturing practice (GMP) manufacturing services for a COVID-19 vaccine.
This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.
April 03, 2020
Advanced analytics and modeling can be used to predict downstream failures, allowing for corrective action before batches are lost.